Abstract

HNRNPA2B1, an RNA-binding protein, plays a key role in primary microRNA processing, alternative splicing, mRNA metabolism and transport. Interestingly, hnRNPA2B1 also works as an N6-methyladenosine (m6A) reader and is critical during tumorigenesis of various tissue types. However, its role in colon cancer is still unclear. In this study, we aimed to elucidate the biological functions of hnRNPA2B1 and to explore its underlying mechanisms in colon cancer. We examined the expression of hnRNPA2B1 in Oncomine and TCGA databases. Then verified the findings in colon cancer cells and clinical samples with western blotting and immunohistochemistry (IHC). We used CRISPR/Cas9 directed gene editing to knockout hnRNPA2B1 expression in human colon cancer cell line SW480 and HCT-116 and carried out both in vivo and in vitro experiments. The results were further confirmed by RNA-seq analyses. We found that hnRNPA2B1 significantly promoted colon cancer cell proliferation both in vitro and in vivo, while knockout of hnRNPA2B1 induced apoptosis and cell cycle arrest in SW480. RNA-seq analyses revealed that the ERK/MAPK pathway was activated by hnRNPA2B1 upregulation. In addition, both hnRNPA2B1 and MAPK pathway were activated in clinical colon cancer specimens and positively correlated. Mechanistically, hnRNPA2B1 appeared to be an upstream regulator of the ERK/MAPK pathway and inhibition of MAPK signaling blocked the effects of hnRNPA2B1. Taken together, our data demonstrated that the RNA-binding protein hnRNPA2B1 promotes cell proliferation and regulates cell cycle and apoptosis of human colon cancer by activating the ERK/MAPK signaling, which may provide a new insight into the development of hnRNPA2B1 as a potential therapeutic target for treatment of colon cancer.

Highlights

  • Colon cancer is the fourth most common malignancy and has the second-highest mortality rate with more than 53,200 estimated deaths occurring in the United States during 2020 (Siegel et al, 2020)

  • We demonstrate that hnRNPA2B1 promotes the progression of colon cancer by regulating the ERK/MAP kinase (MAPK) signaling pathway

  • By analyzing Oncomine and The Cancer Genome Atlas (TCGA) databases, we found that hnRNPA2B1 is highly expressed in colon cancer and is associated with poor disease-free interval and poor prognosis

Read more

Summary

Introduction

Colon cancer is the fourth most common malignancy and has the second-highest mortality rate with more than 53,200 estimated deaths occurring in the United States during 2020 (Siegel et al, 2020). The increasing incidence of colon cancer is more likely to accelerate rapidly due to changes in lifestyle, nutritional habits, population aging, and other factors (Chen et al, 2018). Surgery remains the principal treatment of colon cancer. Since the quality of life in patients with cancer is often greatly affected by the surgery, it is necessary to understand how colon cancer is developed so to come up with novel therapeutic strategies for the diagnosis and treatment of the disease

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call